News
Webcast
Q2 2024 IRIDEX Earnings Conference Call
|
|
Keyword Search
Date | Title | Teaser | |
---|---|---|---|
08/08/24
|
Summary ToggleIridex Reports Second Quarter 2024 Financial Results | MOUNTAIN VIEW, Calif. , Aug. 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results | |
08/05/24
|
Summary ToggleIridex Announces Convertible Note Financing | MOUNTAIN VIEW, Calif. , Aug. 05, 2024 (GLOBE NEWSWIRE) -- IRIDEX Corporation (“Iridex”, or the “Company”) (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, | |
07/30/24
|
Summary ToggleIridex to Report Second Quarter 2024 Financial Results on August 8, 2024 | MOUNTAIN VIEW, Calif. , July 30, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will | |
05/14/24
|
Summary ToggleIridex Reports First Quarter 2024 Financial Results | MOUNTAIN VIEW, Calif. , May 14, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today reported financial results | |
05/08/24
|
Summary ToggleIridex to Report First Quarter 2024 Financial Results on May 14, 2024 | MOUNTAIN VIEW, Calif. , May 08, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced the Company will | |
03/26/24
|
Summary ToggleIridex Reports Fourth Quarter and Full Year 2023 Financial Results | Advances strategic review to unlock shareholder value MOUNTAIN VIEW, Calif. , March 26, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma | |
03/20/24
|
Summary ToggleIridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024 | MOUNTAIN VIEW, Calif. , March 20, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal diseases, today announced it will release | |
02/06/24
|
Summary ToggleIridex Corporation Receives European Patent on MicroPulse Technology | The Advanced Short Pulse Laser System MOUNTAIN VIEW, Calif. , Feb. 06, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical systems, delivery devices, and procedure probes for the treatment of glaucoma and retinal | |
01/24/24
|
Summary ToggleIridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust | MOUNTAIN VIEW, Calif. , Jan. 24, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation , headquartered in Mountain View, California , and Imperial College Healthcare NHS Trust in London , today announced the first patient enrollment in a collaborative medical research study and registry evaluating the | |
01/11/24
|
Summary ToggleIridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma | MOUNTAIN VIEW, Calif. , Jan. 11, 2024 (GLOBE NEWSWIRE) -- Iridex Corporation , a global leader in innovative laser-based medical systems for the treatment of eye diseases, proudly announces the US launch of its next-generation platform Iridex 532 ® and Iridex 577 ® Lasers alongside its 35 th |